Approval · Notice of Compliance 37774 · 2026
EXELON PATCH 10: Notice of Compliance 37774
Issued June 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37774
- Date
- June 24, 2026
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH 10 | Not yet assigned | — |
| EXELON PATCH 15 | Not yet assigned | — |
| EXELON PATCH 5 | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE 9.5 MG per DAY
- RIVASTIGMINE 13.3 MG per DAY
- RIVASTIGMINE 4.6 MG per DAY